Associated Partners

Under IMI2, any legal entity can become an IMI Associated Partner. This page sets out the benefits of joining us as an Associated Partner, and explains how being an Associated Partner works in practice.

 

Who can become an Associated Partner?

The Associated Partner category was created with the goal of opening up our activities to a wider range of stakeholders. As such, examples of organisations that could become IMI Associated Partners include philanthropic organisations and charities that run their own health research programmes, as well as organisations working in sectors related to healthcare such as ICT, imaging, diagnostics, animal health, etc.

 

Benefits of being an Associated Partner

IMI Associated Partners join a vibrant, collaborative health innovation ecosystem, and enjoy benefits such as access to complementary skills, expertise, technology and data; the opportunity to share knowledge and risks in a non-competitive space; and the more efficient use of resources.

As contributors to the project, Associated Partners are involved in the definition of the project, and can participate as observers in IMI Governing Board meetings during discussions relating to the projects they are involved in.

 

IMI Associated Partners

So far, the following organisations have become IMI Associated Partners:

  • Accelerate Diagnostics will contribute to IMI2 - Call 13, topic 3 (The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use).
  • Autism Speaks contributes to the AIMS-2-TRIALS project on autism. They are also involved in the IMI1 project EU-AIMS.
  • Autistica contributes to the AIMS-2-TRIALS project on autism.
  • BD Switzerland Sarl will contribute to IMI2 - Call 13, topic 3 (The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use).
  • Bill and Melinda Gates Foundation contributes to the PERISCOPE project on pertussis (whooping cough) vaccines and will contribute to IMI2 - Call 15, topic 8 (Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic).
  • Bio-rad Laboratories will contribute to IMI2 - Call 13, topic 3 (The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use).
  • Cepheid Europe contributes to the VHFMoDRAD project on diagnostics for Ebola and related diseases.
  • CHDI Foundation will contribute to IMI2 - Call 15, topic 6 (Digital endpoints in neurodegenerative and immune-mediated diseases).
  • Children's Tumor Foundation will contribute under IMI2 - Call 15, topic 1 (Integrated research platforms enabling patient-centric drug development).
  • International Diabetes Federation contributes to the Hypo-RESOLVE project on diabetes.
  • JDRF contributes to the diabetes projects INNODIA, BEAT-DKD and Hypo-RESOLVE. JDRF will also contribute to IMI2 - Call 14, topic 4 (Centre for excellence – remote decentralised clinical trials) and IMI2 - Call 15, topic 4 (Emerging translational safety technologies and tools for interrogating human immuno-biology).
  • Leona M. and Harry B. Helmsley Charitable Trust contributes to the diabetes projects INNODIA and Hypo-RESOLVE.
  • Medicines for Malaria Venture (MMV) will contribute to IMI2 - Call 13, topic 7 (European Screening Centre: unique library for attractive biology (ESCulab)).
  • Parkinson UK will contribute to IMI2 - Call 13, topic 4 (Mitochondrial Dysfunction in Neurodegeneration); IMI2 - Call 13, topic 5 (Support and coordination action for the projects in the neurodegeneration area of the Innovative Medicines Initiative); and IMI2 - Call 15, topic 6 (Digital endpoints in neurodegenerative and immune-mediated diseases).
  • Simons Foundation Autism Research Initiative (SFARI) contributes to the AIMS-2-TRIALS project on autism.
  • Software AG will contribute to IMI2 - Call 12, topic 1 (Development and validation of technology enabled, quantitative and sensitive measures of functional decline in people with early stage Alzheimer’s disease (RADAR-AD)).
  • SpringWorks Therapeutics will contribute to IMI2 - Call 15, topic 1 (Integrated research platforms enabling patient-centric drug development).
  • T1D Exchange, a programme of Unitio, contributes to the Hypo-RESOLVE project on diabetes.
  • TB Alliance will contribute to IMI2 - Call 15, topic 1 (Integrated research platforms enabling patient-centric drug development) and IMI2 - Call 15, topic 8 (Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic).
  • University of Dundee will contribute to IMI2 - Call 15, topic 8 (Accelerator programme Pillar B: Tuberculosis drug development network to accelerate and validate scientific discoveries and advance the R&D pipeline of new and innovative agents to address the global tuberculosis epidemic)
  • Wellcome Trust will contribute to IMI2 - Call 13, topic 3 (The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use).

 

Practical information

Details of how to become an Associated Partner can be found in this information guide.

In summary, organisations wishing to become Associated Partners must apply to the IMI Governing Board with a letter of endorsement (see templates below). In the letter, applicants should set out their acceptance of the IMI2 Statutes; commit to supporting the objectives of IMI2 in their specific area of research; and set out details of their contribution to IMI (e.g. in-kind/cash contributions, activities, duration, etc.). Organisations are requested to use the following templates to prepare their letters:

  • Template for organisations that want to apply to become Associated Partners - doc pdf
  • Template for existing Associated Partners that want to apply to expand the scope of their association, e.g. by contributing to a new Call topic or an existing project - doc pdf

To discuss the Associated Partner option in more detail, contact us